<DOC>
	<DOCNO>NCT01373736</DOCNO>
	<brief_summary>The study design study safety effectiveness 123I-MIBG diagnostic imaging agent evaluate patient know suspected neuroendocrine tumor .</brief_summary>
	<brief_title>123I-MIBG Scintigraphy Patients Being Evaluated Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Subjects must clinical indication 123IMIBG image evaluate presence , extent , status neuroendocrine tumor ; subject must able willing comply study procedure . Subjects history renal insufficiency ( serum creatinine level &gt; 3.0 mg/dL [ 265 Âµmol/L ] ) inability withdrawn medication know interfere 123IMIBG uptake ; Subjects unable tolerate lie supine ; Subjects pregnant breastfeeding , unless information gain outweighs possible hazardous effect 123IMIBG administration . Where assessment risk/benefit ration suggest use 123IMIBG nursing mother , breastfeed discontinue least 48 hour postinjection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>